Zykadia, marketed by Novartis, is an ALK tyrosine kinase inhibitor that blocks proteins that help cancerous cells develop. Before now, there was only one other drug — crizotinib — approved as an ALK tyrosine kinase inhibitor. Zykadia is intended for patients with metastatic ALK-positive NSCLC who previously were treated with crizotinib.
Only 2 to 7 percent of patients with NSCLS are ALK-positive, according to the FDA.
Zykadia was granted breakthrough therapy designation, priority review and orphan product designation. The FDA approved Zykadia through the accelerated approval program, which allows the FDA to approve drugs intended to treat serious or life-threatening diseases based on clinical data demonstrating the drug is likely to have clinical benefit for patients.
More Articles on FDA Approvals:
FDA Approves DNA Test for Primary Cervical Cancer Screening
FDA Approves First Drug to Treat Castleman’s Disease
FDA Proposes Expedited Access Program for Devices Meeting Unmet Needs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
